Dr Hunter Shares Key Takeaways from L-MIND 5-Year Data and RE-MIND2 Study

Video content above is prompted by the following:

• For a patient who does not receive second-line cellular therapy whether based on logistical or clinical reasons, what would be your choice of approved therapies?
  • When choosing a second-line therapy for a patient not eligible for transplant or CAR T-cell therapy, what most impacts your decision? Drug approval? NCCN guidelines? Based on what first-line treatment was received?
• Please review the final 5-year data of the L-MIND study evaluating tafasitamab + lenalidomide.